Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty

Johnson, Stéphanie; Nolan, Richard; Grant, Maree; Price, Glynis; Siafarikas, Aris; Bint, Lewis; Choong, Catherine S

doi:10.1111/j.1440-1754.2011.02083.x

Cited by 20 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neely et al 4) published about a sterile abscess occurring after the use of GnRHa in pediatric patients with CPP for the first time in 1992. Thereafter, several cases of sterile abscess formations after GnRHa depot formulations have been reported in western countries 12 , 13) . In Korea, Kim and Shin 6) reported two cases who have formed sterile abscesses during CPP treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The postulated cause for these reactions is likely to be antibody formation against the biodegradable polymers, which deliver GnRHa drug in a long-acting manner 4 , 12 , 13) . It also thought to be an adverse reaction to the GnRHa peptide itself 12 , 13) . Particularly, leuprolide injection has much higher rates of reaction than other GnRHa.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty

Lee

Kim

Choe

et al. 2014

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

PurposeLong-acting gonadotropin-releasing hormone agonists (GnRHa) are commonly used to treat central precocious puberty (CPP) in Korea. Although rare, there have been reports on the characteristic of adverse reactions of GnRHa in CPP among the Korean population. This study was intended to report on our clinical experience regarding significant adverse reactions to long-acting GnRHa in CPP and early onset puberty and to evaluate the prevalence rate of serious side effects.MethodsThis retrospective study included children with CPP and early onset puberty, who were administered monthly with long-acting GnRHa (leuprolide acetate, triptorelin acetate) at the outpatient clinic of Department of Pediatrics, at Inha University Hospital, between January 2011 and December 2013. We analyzed the clinical characteristics of patients who experienced significant adverse reactions and evaluated the prevalence rate.ResultsSix serious side effects (0.9%) were observed among total of 621 CPP and early onset puberty children with GnRHa therapy. The number of sterile abscess formation was four in three patients (4 events of 621). Anaphylaxis occurred in only one patient, and unilateral slipped capital femoral epiphysis (SCFE) in another one patient. Anaphylaxis occurred after the 6th administration of the monthly depot triptorelin acetate. Unilateral SCFE developed in GnRHa therapy.ConclusionSterile abscess formation occurred in 0.6% of CPP and early onset puberty patients from the administration of a monthly depot GnRHa therapy. The occurrences of anaphylaxis and SCFE are extremely rare, but can have serious implications on patients. Clinicians should be aware of these potential adverse effects related to GnRHa therapy in CPP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty

Lee

Kim

Choe

et al. 2014

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…This medication is indicated for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, the condition of our patient [ 2 ]. GnRHas are the first-line treatment for central precocious puberty (CPP) [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…Established Facts Gonadotropin releasing hormone analogs are the standard of care for central precocious puberty [ 3 ]. Injection site reactions are common from Lupron administration [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Postinjection Muscle Fibrosis from Lupron

Everest

Tsilianidis

Raissouni

et al. 2015

Case Reports in Pediatrics

View full text Add to dashboard Cite

We describe the case of a 6.5-year-old girl with central precocious puberty (CPP), which signifies the onset of secondary sexual characteristics before the age of eight in females and the age of nine in males as a result of stimulation of the hypothalamic-pituitary-gonadal axis. Her case is likely related to her adoption, as children who are adopted internationally have much higher rates of CPP. She had left breast development at Tanner Stage 2, adult body odor, and mildly advanced bone age. In order to halt puberty and maximize adult height, she was prescribed a gonadotropin releasing hormone analog, the first line treatment for CPP. She was administered Lupron (leuprolide acetate) Depot-Ped (3 months) intramuscularly. After her second injection, she developed swelling and muscle pain at the injection site on her right thigh. She also reported an impaired ability to walk. She was diagnosed with muscle fibrosis. This is the first reported case of muscle fibrosis resulting from Lupron injection.

show abstract